//]]>

The Role of Genetics in Breast and Reproductive Cancers (Record no. 17176)

000 -LEADER
fixed length control field 06605nam a22004335i 4500
003 - CONTROL NUMBER IDENTIFIER
control field OSt
005 - DATE AND TIME OF LATEST TRANSACTION
control field 20140310150232.0
007 - PHYSICAL DESCRIPTION FIXED FIELD--GENERAL INFORMATION
fixed length control field cr nn 008mamaa
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION
fixed length control field 100301s2010 xxu| s |||| 0|eng d
020 ## - INTERNATIONAL STANDARD BOOK NUMBER
International Standard Book Number 9781441904775
978-1-4419-0477-5
050 #4 - LIBRARY OF CONGRESS CALL NUMBER
Classification number RC261-271
082 04 - DEWEY DECIMAL CLASSIFICATION NUMBER
Classification number 614.5999
Edition number 23
264 #1 -
-- New York, NY :
-- Springer New York,
-- 2010.
912 ## -
-- ZDB-2-SBL
100 1# - MAIN ENTRY--PERSONAL NAME
Personal name Welcsh, Piri.
Relator term editor.
245 14 - IMMEDIATE SOURCE OF ACQUISITION NOTE
Title The Role of Genetics in Breast and Reproductive Cancers
Medium [electronic resource] /
Statement of responsibility, etc edited by Piri Welcsh.
300 ## - PHYSICAL DESCRIPTION
Extent XX, 260p. 54 illus., 27 illus. in color.
Other physical details online resource.
440 1# - SERIES STATEMENT/ADDED ENTRY--TITLE
Title Cancer Genetics
505 0# - FORMATTED CONTENTS NOTE
Formatted contents note Recognition of Hereditary Breast and Reproductive Cancer Syndromes -- Cancer Genetics in the Clinic: The Challenges and Responsibilities of Counseling and Treating Women at Risk -- Management of Women with Inherited BRCA1 and BRCA2 Mutations -- Genetic etiology of breast and reproductive cancers -- Unclassified Variants in the Breast Cancer Susceptibility Genes BRCA1 and BRCA2 -- Recent Advances in Understanding the Cellular Functions of BRCA1 -- Recent Advances in Understanding the Cellular Functions of BRCA2 -- Genetic Modifiers of Risk of BRCA1- and BRCA2-Related Breast and Ovarian Cancers -- Other Hereditary Breast Cancer Syndromes and Genes -- Ovarian and Endometrial Cancer in Patients with Hereditary Non-polyposis Colorectal Cancer Syndrome -- Somatic Alterations and Implications in Breast Cancer -- Somatic Genetic Development in Epithelial Ovarian Cancer -- Genes and the environment -- High-Frequency Low-Penetrance Alleles -- Host and Viral Genetics and Risk of Cervical Cancer -- Estrogen-Metabolizing Gene Polymorphisms, Genetic Susceptibility, and Pharmacogenomics -- The Future of Discoveries in Breast and Reproductive Cancers: The Genome and Epigenetics.
520 ## - SUMMARY, ETC.
Summary, etc Of all factors contributing to breast cancer, family history of disease is the most powerful. Currently, our understanding of genetic predisposition to breast cancer includes three classes of genes as defined by their associated risks. BRCA1 and BRCA2 are high-penetrance breast cancer predisposition genes. Since the cloning of BRCA1 and BRCA2, inherited mutations in an additional 8 genes, all of which are functionally related to BRCA1 and/or BRCA2, have been shown to variously confer a low-intermediate increased breast cancer risk. Furthermore, recent genome-wide association studies have uncovered eight common variants associated with low-penetrance breast cancer predisposition. Despite these discoveries, most of the familial risk of breast cancer remains unexplained. The Role of Genetics in Breast and Reproductive Cancers is divided into three parts: Recognition of Hereditary Breast and Reproductive Cancer Syndromes, Genetic etiology of breast and reproductive cancers, and Genes and the environment. In the first section, we discuss how genetic counselors and clinicians acknowledge hereditary breast and reproductive cancer syndromes, with an emphasis on the challenges and responsibilities of counseling women in understanding the role of family history in dictating personal cancer risk. This section includes a detailed discussion of the current recommendations for clinical management of women with inherited mutations in BRCA1 and BRCA2. Section II focuses on the impact of inherited mutations in known breast cancer genes on the etiology of breast and reproductive cancers, and the challenges of determining cancer risk when genetic testing reveals variants of unknown consequence in BRCA1 and BRCA2. Because the cellular function of BRCA2 has so elegantly been revealed, we devote a chapter to the current understanding of BRCA2 function and how loss of function contributes to disease development. In addition, we present a discussion of genetic modifiers of risk of BRCA1- and BRCA2-related cancers, and chapters on other hereditary breast cancer syndromes and genes, and ovarian and endometrial cancers in patients with Hereditary Non-Polyposis Colorectal Cancer syndrome. Finally, we conclude this section with two chapters that respectively discuss somatic alterations in breast and in ovarian cancer. The third and final section discusses how recent advances in genomic technologies are being applied to decipher the intricate relationship between genetic variation and the environment, to better predict individual cancer risk, and to development of reagents for disease prevention and treatment. We conclude with a discussion of the role of epigenetics in breast and ovarian cancer development. This final chapter focuses on the exciting prospect that epigenetic changes can be used as predictive and prognostic biomarkers and, because they are reversible, targets for development of pharmacologic reagents to manage disease. Piri L. Welcsh, PhD is a Research Assistant Professor in the Department of Medicine, Division of Medical Genetics at the University of Washington. She received her PhD in Molecular Genetics from The Ohio State University. It was during this time that the seminal paper in which Dr. Mary-Claire King demonstrated that a single gene on chromosome 17, later known as BRCA1, was responsible for many breast and ovarian cancers was published. During Postdoctoral studies at the University of Texas Southwestern Medical Center in Dallas, Dr. Welcsh worked under the guidance of Dr. Anne M. Bowcock and collaborated with Drs. Mary-Claire King and Francis Collins in an attempt to clone BRCA1. Shortly after the gene encoding BRCA1 was identified, Dr. Welcsh joined the research group of Dr. King at the University of Washington where she conducted studies designed to elucidate the biological function of BRCA1. She is currently an independent investigator whose current research goals include the identification and characterization of both genetic and epigenetic mechanisms critical to the development of breast and ovarian cancer.
650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name as entry element Medicine.
Topical term or geographic name as entry element Oncology.
Topical term or geographic name as entry element Human genetics.
Topical term or geographic name as entry element Biomedicine.
Topical term or geographic name as entry element Cancer Research.
Topical term or geographic name as entry element Human Genetics.
Topical term or geographic name as entry element Oncology.
710 2# - ADDED ENTRY--CORPORATE NAME
Corporate name or jurisdiction name as entry element SpringerLink (Online service)
773 0# - HOST ITEM ENTRY
Title Springer eBooks
776 08 - ADDITIONAL PHYSICAL FORM ENTRY
Display text Printed edition:
International Standard Book Number 9781441904768
856 40 - ELECTRONIC LOCATION AND ACCESS
Uniform Resource Identifier http://dx.doi.org/10.1007/978-1-4419-0477-5
942 ## - ADDED ENTRY ELEMENTS (KOHA)
Source of classification or shelving scheme
Item type E-Book
Copies
Price effective from Permanent location Date last seen Not for loan Date acquired Source of classification or shelving scheme Koha item type Damaged status Lost status Withdrawn status Current location Full call number
2014-04-03AUM Main Library2014-04-03 2014-04-03 E-Book   AUM Main Library614.5999

Languages: 
English |
العربية